Consumo de fármacos antitrombóticos en una cohorte de trabajadores

La enfermedad cardiovascular es la primera causa de morbimortalidad en el mundo. Uno de sus pilares del tratamiento se basa en los fármacos antiagregantes y anticoagulantes, con la finalidad de evitar eventos trombóticos. El peso de la evidencia respalda el empleo de estos medicamentos en la prevención secundaria de la enfermedad cardiovascular. No obstante desconocemos las tasas exactas de tratamiento con este tipo de fármacos, en especial en la población joven y sana. Este trabajo tiene como objetivo analizar el consumo de este tipo de medicación en una cohorte de trabajadores jóvenes durante el año 2016. De 5650 sujetos, 602 recibieron al menos una receta de medicación antitrombótica durante el periodo estudiado. La tasa de tratamiento fue del 10,65% (IC95% 9,85-11,45). De estos 602 sujetos, 581 eran hombres (96,51%) frente a 21 mujeres (3,49%). La dosis diaria definida por habitante y día (DHD) mayor fue para el ácido acetil salicílico (AAS) (45,1), seguida del clopidogrel (6,4) y el acenocumarol (3,5). De los datos encontrados puede concluirse que se trata de una cohorte con una tasa no despreciable de medicación antitrombótica, especialmente en hombres, y que todavía existe una infraprescripción de anticoagulantes de acción directa, a pesar de sus beneficios clínicos respecto a los antivitamina K.<br /

Adaptations of the Walking Corsi Test (WalCT) for 2- and 3-year-old preterm and term-born toddlers: a preliminary study

[Abstract] Introduction: Topographical memory is crucial for navigation and environmental representation. The Walking Corsi Test (WalCT) has been used to evaluate topographical memory in children from 4 years upward. The present study aims to determine whether adapted versions of the WalCT- by simplifying instructions and increasing motivation- can be adopted to test topographical memory in 2- and 3-year-old toddlers born at term and preterm. Assessing this skill in such young children is important in light of recent studies that have shown how spatial cognition underlies the development of skills in other cognitive domains as well. Methods: For this purpose, 47 toddlers (27.39 ± 4.34 months, 38.3% females), 20 born at term and 27 preterm, performed two aimed-designed versions of WalCT. Results: The results showed better performance of the term groups with increasing age and for both versions. On the other hand, performance was better in 2-year-old term toddlers vs. preterm. When rising motivation, 2-year-old preterm toddlers improve their performance but differences between both groups were still significant. The preterm group showed lower performance related to lower levels of attention. Discussion: This study provides preliminary data on the suitability of the adapted versions of WalCT in early ages and prematurity conditions.Ministerio de Ciencia e Innovación (España); PID2021-126782OA-I0

Measuring spatial navigation during locomotion in children: a systematic review

Reviwe[Abstract] Spatial navigation allows us to move around our environment, walking being the most advanced form of human locomotion. Over the years, a range of tools has been developed to study spatial navigation in children. Aim. To describe the role of locomotion during the assessment of spatial navigation in children, providing an overview of the instruments available for assessing spatial navigation in typically developing children and those with neurodevelopmental disorders. Methods and Procedures. A systematic search was performed in six electronic databases between December 2022 and February 2023, then updated in July 2023. Cross-sectional and observational studies were included. Outcomes and results. Of the 3,385 studies screened, 47 were selected for this review. Five studies described the influence of locomotion on spatial navigation, and seven studies included locomotion as an explanatory variable in this area. Most studies focused on children from five to twelve years old, whereas only nine were centred on infants and preschoolers. Just eight assessed spatial abilities in individuals with neurodevelopmental disorders. Conclusions and implications. Children with or at risk of neurodevelopmental impairments show poorer spatial navigation skills. Having the choice to actively explore the space is more important than the way they locomote. It is necessary to have tools to assess spatial navigation during locomotion early in infancy.This research was funded by the Spanish Ministry of Science and Innovation, the State Research Agency, the FEDER (PID2021-126782OA-100) received by Verónica Robles García and by the Ateneo Grant 2022 N. RG1221816BE8DDFE received by Laura PiccardiEspaña. Ministerio de Ciencia e Innovación; PID2021-126782OA-10

The Spanish HIV BioBank: a model of cooperative HIV research

<p>Abstract</p> <p>Background</p> <p>The collection of samples from HIV-infected patients is the beginning of the chain of translational research. To carry out quality research that could eventually end in a personalized treatment for HIV, it is essential to guarantee the availability, quality and traceability of samples, under a strict system of quality management.</p> <p>Methods</p> <p>The Spanish HIV BioBank was created with the objectives of processing, storing and providing distinct samples from HIV/AIDS patients, categorized according to strictly defined characteristics, free of charge to research projects. Strict compliance to ethical norms is always guaranteed.</p> <p>Results</p> <p>At the moment, the HIV BioBank possesses nearly 50,000 vials containing different prospective longitudinal study sample types. More than 1,700 of these samples are now used in 19 national and international research projects.</p> <p>Conclusion</p> <p>The HIV BioBank represents a novel approach to HIV research that might be of general interest not only for basic and clinical research teams working on HIV, but also for those groups trying to establish large networks focused on research on specific clinical problems. It also represents a model to stimulate cooperative research among large numbers of research groups working as a network on specific clinical problems. The main objective of this article is to show the structure and function of the HIV BioBank that allow it to very efficiently release samples to different research project not only in Spain but also in other countries.</p

Exploring the impact of COVID-19 on newborn neurodevelopment: a pilot study.

The COVID-19 pandemic can seize the opportunity to explore the hypothesis of prenatal exposure to viral infections increases the risk for neurodevelopmental disorders. Advancing our knowledge in this regard would improve primary prevention of mental disorders in children. For this pilot study, six-week-old infants born to mothers exposed (n = 21) or unexposed (n = 21) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were assessed in Santander-Cantabria (Spain) using the Neonatal Behavioral Assessment Scale (NBAS). Groups comparisons were performed to explore the effects that infection and timing of exposure (in terms of the three trimesters of pregnancy). The infants' competencies and performances on the NBAS were generally similar in the exposed and unexposed to SARS-CoV-2 groups. The most significant difference found was a less optimally response to cuddliness (item on the state regulation domain) particularly in infants born to mothers exposed in the third trimester of pregnancy, and in pull-to-sit (item on the motor system domain). Although our interpretations must be careful, these preliminary results highlight the possible association between prenatal SARS-CoV-2 exposure and poorer development in motor skills and infant interactive behavior. Further longitudinal studies are needed to explore these relationships and disentangle the biological mechanisms implicated

Modified Serum ALP Values and Timing of Apparition of Knee Epiphyseal Ossification Centers in Preterm Infants with Cholestasis and Risk of Concomitant Metabolic Bone Disease of Prematurity

The usefulness of serum alkaline phosphatase (ALP) and phosphorous in screening and monitoring of metabolic bone disease of prematurity (MBDP) still has some limitations, especially in preterm infants with concomitant conditions such as cholestasis. We aimed to assess a modification of serum ALP (M-ALP) as a biomarker for MBDP in preterm infants, and the use of ultrasound monitoring for the apparition of knee ossification centers as marker of bone mineralization. Biochemical and clinical registers were taken from 94 preterm newborns 1 was demonstrated to be more specific (87.5%) in the diagnosis of MBDP than the cut-off value of serum ALP > 500 IU/L (62.5%). ALP/M-ALP > 1 showed 100% sensitivity and specificity for the diagnosis of MBDP, and a good correlation with specific bone ALP (B-ALP). Patients with the knee nucleus by post-menstrual week 37 had lower B-ALP compared to patients with no nucleus, and no patients with MBDP presented the nucleus by the 40th week. In the absence of reliable specific B-ALP, reinterpreting serum ALP values by M-ALP plus monitoring of knee ossification centers contribute to better management of MBDP in preterm infants with cholestasis

Modelling the consumption of anxiolytics and its addictive behaviour

Background: Population-based anxiolytics consumption (AX) is a widely debated subject because long-term AX may lead to tolerance and addiction. This study aims to obtain mathematical models that identify the various behaviours in AX prescription in accordance with gender, age and the continuous prescription of other drugs associated with chronic diseases.Methods: Data were obtained from an electronic prescriptions database (n=12,211,992) received by patients (n=504,224) visiting the Primary Health Care Centres in the province of Castellón (East Spain) in 2009. A linear regression model was used to explain the number of defined daily doses (DDD) of AX prescribed in accordance with age, gender and more than 5 prescriptions of any drug associated with chronic diseases other than AX. We used the logistic regression model to quantify the joint influence of the explanatory variables on the likelihood (L) of prescribing increasingly high DDD of AX.Results: The mean annual DDD per patient was 133.13, and the DDD prescribed was 38.06 day/1000 inhabitants. Few differences, although significant, in prescriptions per gender were observed; males received fewer prescriptions than females. Conversely, differences in age groups were substantial; the older subjects become, the higher the prescribed DDD, although these differences disappeared after the age of 65. AX use was also positively associated with the presence of comorbidity: depression, psychosis and epilepsy. Sporadic AX prescriptions were not associated with any factor, except continuous use.Conclusions: The prevalence of prescribing AX in the general population visiting the primary health centres in Castellón is over 16%. Prescriptions and the DDD of AX are barely higher for females than for males, and age is the most influential factor; the older the patient, the higher the number of prescribed DDD. The likelihood of potentially addictive behaviours is higher among the elderly and patients with comorbidity, mainly those patients with other chronic psychiatric conditions. © 2010 Elsevier Ltd.Guadalajara Olmeda, MN.; Barrachina Martínez, I.; De La Poza, E.; Vivas Consuelo, DJJ.; Caballer Tarazona, M. (2011). Modelling the consumption of anxiolytics and its addictive behaviour. Mathematical and Computer Modelling. 54(7):1626-1633. https://doi.org/10.1016/j.mcm.2010.12.036S1626163354

Alternative consent methods used in the multinational, pragmatic, randomised clinical trial SafeBoosC-III

Background The process of obtaining prior informed consent for experimental treatment does not fit well into the clinical reality of acute and intensive care. The therapeutic window of interventions is often short, which may reduce the validity of the consent and the rate of enrolled participants, to delay trial completion and reduce the external validity of the results. Deferred consent and ‘opt-out’ are alternative consent methods. The SafeBoosC-III trial was a randomised clinical trial investigating the benefits and harms of cerebral oximetry monitoring in extremely preterm infants during the first 3 days after birth, starting within the first 6 h after birth. Prior, deferred and opt-out consent were all allowed by protocol. This study aimed to evaluate the use of different consent methods in the SafeBoosC-III trial, Furthermore, we aimed to describe and analyse concerns or complaints that arose during the first 6 months of trial conduct. Methods All 70 principal investigators were invited to join this descriptive ancillary study. Each principal investigator received a questionnaire on the use of consent methods in their centre during the SafeBoosC-III trial, including the possibility to describe any concerns related to the consent methods used during the first 6 months of the trial, as raised by the parents or the clinical staff. Results Data from 61 centres were available. In 43 centres, only prior informed consent was used: in seven, only deferred consent. No centres used the opt-out method only, but five centres used prior and deferred, five used prior, deferred and opt-out (all possibilities) and one used both deferred and opt-out. Six centres applied to use the opt-out method by their local research ethics committee but were denied using it. One centre applied to use deferred consent but was denied. There were only 23 registered concerns during the execution of the trial. Conclusions Consent by opt-out was allowed by the protocol in this multinational trial but only a few investigators opted for it and some research ethics boards did not accept its use. It is likely to need promotion by the clinical research community to unfold its potential

Respiratory and mental health effects of wildfires: an ecological study in Galician municipalities (north-west Spain)

<p>Abstract</p> <p>Background</p> <p>During the summer of 2006, a wave of wildfires struck Galicia (north-west Spain), giving rise to a disaster situation in which a great deal of the territory was destroyed. Unlike other occasions, the wildfires in this case also threatened farms, houses and even human lives, with the result that the perception of disaster and helplessness was the most acute experienced in recent years. This study sought to analyse the respiratory and mental health effects of the August-2006 fires, using consumption of anxiolytics-hypnotics and drugs for obstructive airway diseases as indicators.</p> <p>Methods</p> <p>We conducted an analytical, ecological geographical- and temporal-cluster study, using municipality-month as the study unit. The independent variable was exposure to wildfires in August 2006, with municipalities thus being classified into the following three categories: no exposure; medium exposure; and high exposure. Dependent variables were: (1) anxiolytics-hypnotics; and (2) drugs for obstructive airway diseases consumption. These variables were calculated for the two 12-month periods before and after August 2006. Additive models for time series were used for statistical analysis purposes.</p> <p>Results</p> <p>The results revealed a higher consumption of drugs for obstructive airway diseases among pensioners during the months following the wildfires, in municipalities affected versus those unaffected by fire. In terms of consumption of anxiolytics-hypnotics, the results showed a significant increase among men among men overall -pensioners and non-pensioners- in fire-affected municipalities.</p> <p>Conclusions</p> <p>Our study indicates that wildfires have a significant effect on population health. The coherence of these results suggests that drug utilisation research is a useful tool for studying morbidity associated with environmental incidents.</p

Comparative efficacy of two primary care interventions to assist withdrawal from long term benzodiazepine use: A protocol for a clustered, randomized clinical trial

<p>Abstract</p> <p>Background</p> <p>Although benzodiazepines are effective, long-term use is not recommended because of potential adverse effects; the risks of tolerance and dependence; and an increased risk of hip fractures, motor vehicle accidents, and memory impairment. The estimated prevalence of long-term benzodiazepine use in the general population is about 2,2 to 2,6%, is higher in women and increases steadily with age. Interventions performed by General Practitioners may help patients to discontinue long-term benzodiazepine use. We have designed a trial to evaluate the effectiveness and safety of two brief general practitioner-provided interventions, based on gradual dose reduction, and will compare the effectiveness of these interventions with that of routine clinical practice.</p> <p>Methods/Design</p> <p>In a three-arm cluster randomized controlled trial, general practitioners will be randomly allocated to: a) a group in which the first patient visit will feature a structured interview, followed by visits every 2-3 weeks to the end of dose reduction; b) a group in which the first patient visit will feature a structured interview plus delivery of written instructions to self-reduce benzodiazepine dose, or c) routine care. Using a computerized pharmaceutical prescription database, 495 patients, aged 18-80 years, taking benzodiazepine for at least 6 months, will be recruited in primary care health districts of three regions of Spain (the Balearic Islands, Catalonia, and Valencia). The primary outcome will be benzodiazepine use at 12 months. The secondary outcomes will include measurements of anxiety and depression symptoms, benzodiazepine dependence, quality of sleep, and alcohol consumption.</p> <p>Discussion</p> <p>Although some interventions have been shown to be effective in reducing benzodiazepine consumption by long-term users, the clinical relevance of such interventions is limited by their complexity. This randomized trial will compare the effectiveness and safety of two complex stepped care interventions with that of routine care in a study with sufficient statistical power to detect clinically relevant differences.</p> <p>Trial Registration</p> <p>Current Controlled Trials: <a href="http://www.controlled-trials.com/ISRCTN13024375">ISRCTN13024375</a></p